Angiogenesis, cancer, diabetic retinopathy, tilted peptide

Antiangiogenic therapy appears as a promising approach for treating many pathologies  i.e. cancer, diabetic retinopathy, age-related macular degeneration, rheumatoid arthritis … .

 

We have previously identified N-terminal 16K fragments of the human prolactin/growth hormone family as potential angiogenesis inhibitors. In particular, 16K prolactin has been shown to prevent tumor growth (prostate, colon…) and retinopathy in mouse models. 16K prolactin-isolated peptide inhibits angiogenesis both in vitro and in vivo. Later, in collaboration with the University Faculty of Gembloux, structurally-related peptides, comprising 11 to 40 amino acids and based on a tilted peptide structure, have been identified as angiogenic inhibitors. Experimental tumor studies are underway.

The present invention refers to a pharmaceutical composition comprising such an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide.

Early Stage

Patent application under prosecution WO 2006/018418 A2

Research collaboration for license agreement